Director-Affiliated Fund Sells $173.7M in Kymera Therapeutics Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (5.7× avg).
Summary
An investment group affiliated with a director of Kymera Therapeutics sold $173.7 million worth of common stock, representing a significant reduction in their stake.
Key Events · Ownership and Investor Activity · KYMR
-
Major Insider Sale
An investment group, Biotechnology Value Fund, affiliated with a director, sold 1,630,658 shares of common stock.
-
Substantial Value
The total value of the shares sold was $173,665,077.
-
Significant Market Impact
This sale represents approximately 1.95% of Kymera Therapeutics' current market capitalization.
-
Accelerated Distribution
This single transaction significantly increases the net insider selling activity, which was already negative over the past 90 days.
Analysis · KYMR · Finance
This significant open-market sale by a director-affiliated institutional investor represents nearly 2% of the company's market capitalization. The substantial size of this disposition, which exceeds the total net insider sales over the past 90 days, indicates a notable reduction in conviction from a major shareholder and could create selling pressure.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1062 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $108.12 on NASDAQ in the Finance sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.